Department of Internal Medicine, Division of Internal and Cardiovascular Medicine, University of Perugia, Via E. dal Pozzo, 06126 Perugia, Italy.
Cardiovasc Res. 2012 Jun 1;94(3):428-38. doi: 10.1093/cvr/cvs100. Epub 2012 Feb 23.
The aim of the present study was to assess whether the addition of a nitric oxide (NO)-donating moiety to atorvastatin enhances anti-inflammatory and anti-atherogenic effects in an animal model of endothelial dysfunction, systemic peroxidation and inflammation, and accelerated atherosclerosis.
Low-density lipoprotein receptor (LDLR)(-/-) mice kept on a high-fat diet (HFD) for 16 weeks underwent photochemical injury to the femoral artery with the local production of oxygen radicals. HFD markedly enhanced cholesterol, inflammatory biomarkers in plasma and in the femoral arterial wall, and atherosclerotic lesions in the aortic arch; inflammation and atherosclerosis were further increased by photochemically generated oxygen radicals. Treatment with the NO-donating atorvastatin NCX 6560 (11.7 mg/kg) was significantly more effective than atorvastatin (10 mg/kg) in reducing the following parameters: lipid-rich lesions in the aortic arch (surface covered: atorvastatin = 24 ± 5%; NCX 6560 = 14.7 ± 3.9%; P< 0.05); the production of radical oxygen species in the aorta (dichlorofluorescein fluorescence intensity per milligram of protein: atorvastatin = 2419 ± 136.7; NCX 6560 = 1766 ± 161.2; P< 0.05); femoral artery intima/media thickness (atorvastatin = 1.2 ± 0.11; NCX 6560 = 0.3 ± 0.14; P< 0.05); circulating interleukin-6 (atorvastatin = 34.3 ± 6.8 pg/mL; NCX 6560 = 17.7 ± 14.4 pg/mL; P< 0.05); and matrix metalloproteinase 2 in the arterial wall (atorvastatin = 55.2 ± 1.9 ng/µg of proteins; NCX 6560 = 45.8 ± 2.6 ng/µg of proteins; P < 0.05).
In conditions of severe endothelial dysfunction, systemic peroxidation and inflammation, and accelerated atherosclerosis, atorvastatin, even at high doses, displays suboptimal anti-atherogenic and anti-inflammatory effects, while the addition of a NO-donating property confers enhanced anti-atherogenic and anti-inflammatory effects.
本研究旨在评估将一氧化氮(NO)供体部分添加到阿托伐他汀中是否能增强内皮功能障碍、全身性过氧化和炎症以及加速动脉粥样硬化动物模型中的抗炎和抗动脉粥样硬化作用。
16 周高脂饮食(HFD)喂养的低密度脂蛋白受体(LDLR)(-/-)小鼠进行股动脉光化学损伤,局部产生氧自由基。HFD 显著增加了血浆和股动脉壁中的胆固醇、炎症生物标志物,以及主动脉弓中的动脉粥样硬化病变;光化学产生的氧自由基进一步增加了炎症和动脉粥样硬化。与阿托伐他汀(10 mg/kg)相比,NO 供体阿托伐他汀 NCX 6560(11.7 mg/kg)治疗在以下参数方面更有效:主动脉弓中的富含脂质病变(表面覆盖:阿托伐他汀=24±5%;NCX 6560=14.7±3.9%;P<0.05);主动脉中产生的活性氧种类(每毫克蛋白的二氯荧光素荧光强度:阿托伐他汀=2419±136.7;NCX 6560=1766±161.2;P<0.05);股动脉内膜/中膜厚度(阿托伐他汀=1.2±0.11;NCX 6560=0.3±0.14;P<0.05);循环白细胞介素-6(阿托伐他汀=34.3±6.8 pg/mL;NCX 6560=17.7±14.4 pg/mL;P<0.05);以及动脉壁中的基质金属蛋白酶 2(阿托伐他汀=55.2±1.9 ng/µg 蛋白质;NCX 6560=45.8±2.6 ng/µg 蛋白质;P<0.05)。
在严重的内皮功能障碍、全身性过氧化和炎症以及加速的动脉粥样硬化情况下,即使高剂量的阿托伐他汀也表现出亚最佳的抗动脉粥样硬化和抗炎作用,而添加一氧化氮供体可增强抗动脉粥样硬化和抗炎作用。